When covid-19 vaccines meet the new variants of the virus
A lot depends on blocking transmission, not just disease
ON FEBRUARY 1ST researchers around the world saw the tweet for which they had been waiting: “We say with caution, the magic has started”. Eran Segal, a scientist at the Weizmann Institute, had been posting regular updates on the course of Israel’s covid-19 epidemic since its mass vaccination campaign had begun six weeks earlier. By February 1st he was seeing the number of hospitalisations dropping significantly among the over-60s—a cohort in which the number vaccinated had reached 70%, seen as a crucial level, three weeks before. After an expected but still somewhat nail-biting lag, the vaccine was doing its thing.
This article appeared in the Briefing section of the print edition under the headline “Obstacle course”
From the February 13th 2021 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from Briefing
Even in India, bureaucracy is being curtailed
Many small steps could make a big difference
Many governments talk about cutting regulation but few manage to
Yet radical deregulation is often a big boost to growth
Why Chinese AI has stunned the world
DeepSeek’s models are much cheaper and almost as good as American rivals
The right in Congress and the courts will reshape Donald Trump’s agenda
As dominant as the new president is, there is still life in Washington’s institutions
How far will Donald Trump go to get rid of illegal immigrants?
It is his signature policy, but the obstacles are daunting
Young customers in developing countries propel a boom in plastic surgery
Falling costs and converging beauty standards spur new habits